Orforglipron vs Semaglutide: oral vs injectable
A side-by-side comparison of Orforglipron, Semaglutide by independent evidence grade, FDA status, mechanism of action, key safety considerations, and which FDA 503B outsourcing facilities report compounding each.
| Orforglipron | Semaglutide | |
|---|---|---|
| Evidence grade | Grade A: Approved and proven | Grade A: Approved and proven |
| FDA status | FDA approved FDA-approved April 1, 2026, for obesity (BMI at least 30 kg/m²) or overweight (BMI at least 27 kg/m²) with at least one weight-related comorbidity. | FDA approved Approved as Ozempic (subcutaneous injection, type 2 diabetes), Wegovy (subcutaneous injection 2.4 mg and oral 25 mg tablet, chronic weight management and cardiovascular risk reduction in obesity), and Rybelsus (oral tablet, type 2 diabetes). |
| Mechanism | Non-peptide small molecule that selectively activates the GLP-1 receptor, suppressing appetite through central and peripheral pathways, slowing gastric emptying, and enhancing glucose-dependent insulin secretion. | Semaglutide is a GLP-1 receptor agonist that stimulates glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite via central and peripheral GLP-1 receptor activation. |
| Key safety | Foundayo carries an FDA boxed warning for thyroid C-cell tumors: GLP-1 receptor agonists pharmacologically active in rodents have caused thyroid C-cell... | Boxed warning: semaglutide causes thyroid C-cell tumors in rodents at clinically relevant exposures; human relevance is unknown but it is contraindicated in... |
Key differences
Orforglipron and Semaglutide hold the same evidence grade (A): grade a: approved and proven. Both are fda approved. Mechanistically, Orforglipron works by non-peptide small molecule that selectively activates the glp-1 receptor, suppressing appetite through central and peripheral pathways, slowing gastric emptying, and enhancing glucose-dependent insulin secretion, whereas Semaglutide works by semaglutide is a glp-1 receptor agonist that stimulates glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite via central and peripheral glp-1 receptor activation.
What the evidence shows
Orforglipron A
Orforglipron (brand name Foundayo) is a non-peptide oral small-molecule GLP-1 receptor agonist developed by Eli Lilly, approved by FDA on April 1, 2026, for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity, in combination with a reduced-calorie diet and...
Compounding: FDA-approved branded product (Foundayo); compounding is not appropriate. As a small-molecule drug, it is not a biologic and not on peptide compounding lists. Dispensing requires a valid prescription;...
Semaglutide A
Semaglutide has the broadest and strongest human evidence base among GLP-1 receptor agonists currently approved for weight management and type 2 diabetes. The STEP clinical trial program, comprising multiple large phase 3 randomized controlled trials, demonstrated clinically meaningful weight loss in adults with...
Compounding: FDA-approved; brand and generic forms available. Mass compounding from bulk API by 503A and 503B facilities was permitted during a declared shortage; the semaglutide shortage was resolved by FDA in...
Where these are compounded
Orforglipron: no FDA 503B facility in our directory currently reports compounding it.
Semaglutide: reported compounded by Annovex Pharma, Inc., Apollo Care, BPI Labs LLC, Delta Pharma, Inc., Eagle Pharma, Empower Clinic Services New Jersey, Empower Pharma, Fagron Compounding Services dba Fagron Sterile Services, and 9 more.
From the FDA Outsourcing Facility Product Report. PeptideGrids does not sell or source any compound.
Frequently asked questions
Is Orforglipron or Semaglutide FDA approved?
Orforglipron is fda approved. Semaglutide is fda approved.
Which has stronger clinical evidence, Orforglipron or Semaglutide?
Both hold grade A. PeptideGrids grades evidence A to D; see each compound page for the cited trials.
What is the difference between Orforglipron and Semaglutide?
Orforglipron: Non-peptide small molecule that selectively activates the GLP-1 receptor, suppressing appetite through central and.... Semaglutide: Semaglutide is a GLP-1 receptor agonist that stimulates glucose-dependent insulin secretion, suppresses glucagon, slows....
Full profiles: Orforglipron, Semaglutide. Browse all GLP-1s and therapeutic peptides.